Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline

MB Demay, AG Pittas, DD Bikle, DL Diab… - The Journal of …, 2024 - academic.oup.com
Background Numerous studies demonstrate associations between serum concentrations of
25-hydroxyvitamin D (25 [OH] D) and a variety of common disorders, including …

Wastewater-based surveillance as a tool for public health action: SARS-CoV-2 and beyond

MD Parkins, BE Lee, N Acosta, M Bautista… - Clinical microbiology …, 2024 - journals.asm.org
Wastewater-based surveillance (WBS) has undergone dramatic advancement in the context
of the coronavirus disease 2019 (COVID-19) pandemic. The power and potential of this …

Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants

B Kampmann, SA Madhi, I Munjal… - … England Journal of …, 2023 - Mass Medical Soc
Background Whether vaccination during pregnancy could reduce the burden of respiratory
syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is …

Nirsevimab for prevention of hospitalizations due to RSV in infants

SB Drysdale, K Cathie, F Flamein, M Knuf… - … England Journal of …, 2023 - Mass Medical Soc
Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract …

RSV prefusion F protein–based maternal vaccine—preterm birth and other outcomes

I Dieussaert, J Hyung Kim, S Luik, C Seidl… - … England Journal of …, 2024 - Mass Medical Soc
Background Vaccination against respiratory syncytial virus (RSV) during pregnancy may
protect infants from RSV disease. Efficacy and safety data on a candidate RSV prefusion F …

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with …

EAF Simões, SA Madhi, WJ Muller… - The Lancet Child & …, 2023 - thelancet.com
Background In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-
life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants …

Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and …

M Bardsley, RA Morbey, HE Hughes… - The Lancet Infectious …, 2023 - thelancet.com
Background Seasonal epidemics of respiratory syncytial virus (RSV) cause a clinically
significant burden of disease among young children. Non-pharmaceutical interventions …

Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from …

RG Bender, SB Sirota, LR Swetschinski… - The Lancet Infectious …, 2024 - thelancet.com
Summary Background Lower respiratory infections (LRIs) are a major global contributor to
morbidity and mortality. In 2020–21, non-pharmaceutical interventions associated with the …

The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study

JG Wildenbeest, MN Billard, RP Zuurbier… - The Lancet …, 2023 - thelancet.com
Background Respiratory syncytial virus (RSV) is a major cause of hospitalisation in infants.
The burden of RSV infection in healthy term infants has not yet been established. Accurate …

Respiratory syncytial virus infection and novel interventions

AC Langedijk, LJ Bont - Nature Reviews Microbiology, 2023 - nature.com
The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in
young children and older adults has gained increased recognition in recent years. Recent …